Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
94 hedge funds and large institutions have $252M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 29 reducing their positions, and 11 closing their positions.
417% more call options, than puts
Call options by funds: $2.98M | Put options by funds: $577K
103% more capital invested
Capital invested by funds: $124M → $252M (+$128M)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
11% more funds holding
Funds holding: 85 → 94 (+9)
3% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.96M |
| 2 |
VA
VR Adviser
New York
|
+$7.74M |
| 3 |
Morgan Stanley
New York
|
+$5.28M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.13M |
| 5 |
Barclays
London,
United Kingdom
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$1.66M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$1.07M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$960K |
| 4 |
PA
Perceptive Advisors
New York
|
-$726K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$627K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
101
Trexquant Investment
Stamford,
Connecticut
| – | -$94K | -602 | Closed |
|
|
ECM
102
ExodusPoint Capital Management
New York
| – | -$69K | -442 | Closed |
|
103
ProShare Advisors
Bethesda,
Maryland
| – | -$62K | -393 | Closed |
|
104
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$22K | -144 | Closed |
|
EIGR Hedge Fund Activity: Q1 2022 in Review
94 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2022, worth a combined $252M — up 103% from $124M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EIGR positions and 11 closed out — a net gain of 9 holders — while 28 added to existing stakes and 29 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $8.96M. The largest seller was Russell Investments Group, exiting entirely with an estimated $1.66M sold.
- 94 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2022, up from 85 in Q4 2021.
- Funds reported $252M of Eiger BioPharmaceuticals, Inc. stock for Q1 2022, up 103% quarter-over-quarter.
- 20 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2022 and 11 closed out, a net change of +9 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2022 was Adage Capital Partners, an estimated $8.96M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2022 was Russell Investments Group, an estimated $1.66M sold.
Based on aggregated 13F filings for Q1 2022.